What you should know:
1. Omeros’ preliminary total and Omidria 1 percent/0.3 percent revenues for the fourth quarter are expected to reach $22 million, a year-over-year increase of $13.8 million and a quarterly increase of $4.6 million.
2. The growth reflects strong demand for Omidria from ASCs and hospitals
3. Pass-through reimbursement for Omidria was reinstated Oct. 1, 2018, spurring higher demand.
4. Units sold by wholesalers to ASCs and to hospitals also hit a record high in the fourth quarter of 2018.
5. Omeris is using growing revenues from Omidria to advance pipeline progress, including its phase 3 program in hematopoietic stem cell transplant-associated thrombotic microangiopathy.
More articles on supply chain:
ASC supply chain tip of the day: Use best practices for technology
GI center supply chain management — The big pain points and how Yuma Endoscopy Center is becoming more efficient, cost-effective
ASC supply chain tip of the day: Collaborate with physicians to standardize products
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.